PALM BEACH, Florida, November 30, 2017 /PRNewswire/ --
Withoutthe influence of CBD Oil and Cannabis infusion, according to Markets and Markets , the nutraceutical ingredients market alone is projected to grow at a CAGR of 7.5% from 2016 to 2022 to reach USD 445.58 Billion by 2022.
CNRP Mining Inc. (OTCQB: CRPGF) (CSE: CND.CN) is pleased to announce that X-SPRAYS has signed an exclusive distribution agreement with a national distributor of consumer packaged goods in Europe (the "Distributor"). Under the terms of the agreement the Distributor will supply X-SPRAYS products to the following countries: Germany, Austria and Switzerland. Read this and more news for CRPGF and its X-Sprays products at http://www.marketnewsupdates.com/news/crpgf.html. The Distributor has a 10-year history and multiple existing retail channels, including pharmacies, drug stores and a robust online presence. X-SPRAYS products will be supplied leveraging the Distributor's extensive network and this partnership provides X-SPRAYS with unique access to the European market. The Company will begin shipping products to the Distributor in early Q1-2018, pending necessary approvals. With a population exceeding 82 million people and federal insurance coverage for cannabis, Germany represents the world's largest legal cannabis market. "We are excited to have partnered with an established and recognized leader in the European consumer packaged goods marketplace. This agreement allows us to utilize an existing network with wide reach to immediately create a presence in the world's largest federally legislated medicinal cannabis market," said Mr. John Knapp, CEO of X-SPRAYS. In other industry development and happens around the market: Liberty Leaf Holdings Ltd. (CSE: LIB.CN) (OTCQB: LIBFF) (CNQ: LIB) this week, the company announced the appointment of Mr. Doug Macdonell to its Board of Directors. Mr. Macdonell is a retired RCMP officer and recognized expert in the field of cannabis and cannabis cultivation. During his extensive RCMP career, he initiated and supervised legal marijuana grow facilities in Vancouver and Edmonton for the purpose of training RCMP and City Police personnel to become specialists in the cannabis industry. In addition to training law enforcement, Mr. Macdonell is recognized as an expert witness in cannabis, cannabis production and distribution at all levels of the Canadian court system. He has lectured extensively to other agencies such as the Drug Enforcement Agency in the U.S. and the Department of Justice Personnel in Canada. Since retiring from the RCMP, Mr. Macdonell has served two terms as a City Councillor for the City of Coquitlam and has sat on the Boards of several civic organizations.
Future Farm Technologies Inc. (CSE: FFT.CN) (OTCQB: FFRMF) (CNQ: FFT) announced this week that it has closed on the previously announced acquisition of a 120-acre industrial hemp farm in Amity, ME. With this acquisition, Future Farm is now strategically positioned in both the fast-growing hemp market as well as the cannabis market. Future Farm expects to harvest 1,700 plants per acre of the 120-acre farm, which translates into approximately 10-kilos of CBD distillate per acre, which further translates into $90,000 per acre in revenue, or on 120-acres projected revenue of $10,800,000.00. With Maine's current favorable economic climate for hemp in place, the Company is moving aggressively to acquire more land and is in discussion with existing farm operators to farm another 200-acres of organic hemp on existing farmland in Maine.
Tetra-Biopharma Inc. (TSX-V: TBP.V) (OTCQB: TBPMF) (CDNX: TBP) recently announced that it is partnering with a major manufacturer of controlled active pharmaceutical ingredients (APIs) in the USA for the manufacturing of Dronabinol XL AdVersaŽ as the Company accelerates its plans to submit a 505(b) (2) New Drug Application (NDA) for the treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. According to market research by the International Agency for Research on Cancer 2, the global chemotherapy-induced nausea and vomiting (CINV) market will reach a valuation of US$1.88 bn by 2020, rising from its 2013 valuation of US$1.28 bn. Based on the expected improved safety profile of a delayed release Dronabinol, Tetra expects that the AdversaŽ tablet can gain an important share of this market within three (3) years of its launch in the USA, with sales of AdversaŽ that could potentially reach $30,000,000 USD at the end of the third year of sales.
OrganiGram Holdings Inc. (TSX-V: OGI.V) (OTCQB: OGRMF) (CDNX: OGI) announced yesterday it launched The Edison Project. The Edison Project is an initiative designed to produce and offer Organigram patients the very highest quality flower possible using the latest in technology and industry best practices. "The Edison Project represents our very best work to date," says Ray Gracewood, Organigram's Chief Commercial Officer. "We're most proud of these strains of medicine because they're a product of our intensive research on the biology of cannabis and continuous improvement in production. We've adopted a culture of refusing to settle at Organigram; it's evolved such that we've come to discover more about the true potential in our plants and we've learned how to deliver the benefit of that potential to our patients."
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated twenty-three hundred dollars for news coverage of the current press release issued by CNRP Mining Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information: E-mail: firstname.lastname@example.org +1-561-325-8757
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...View All